Great Basin Scientific Inc (GBSN) 0.09 $GBSN Technical

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Great Basin Scientific Inc (GBSN) 0.09 $GBSN

Technical Coverage on Financial and Healthcare Stocks - CBOE Holdings, Boston Private, AEterna Zentaris, Great Basin Scientific and Gilead Sciences
PR Newswire - Mon Sep 28, 8:03AM CDT
ACI Association has initiated research coverage on the following equities: CBOE Holdings, Inc. (NASDAQ: CBOE), Boston Private Financial Holdings, Inc. (NASDAQ: BPFH), AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), CBOE: 67.32 (+0.07), GBSNU: 16.22 (-0.28), GILD: 98.28 (+0.01), AEZS: 0.09 (unch), BPFH: 11.54 (-0.14)

Medical Laboratories and Research Stocks Scanner -- Great Basin Scientific, Agilent Technologies, Thermo Fisher Scientific, Exact Sciences, and DexCom
PR Newswire - Thu Sep 24, 7:21AM CDT
Equity Research Institute has initiated coverage on the following equities: Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), Exact Sciences Corporation (NASDAQ: EXAS), and DexCom Inc. (NASDAQ: DXCM). Free research report on Great Basin Scientific can be accessed at https://www.erionline.net/GBSN.pdf On Wednesday, September 23, 2015, the NASDAQ Composite ended at 4,752.74, down 0.08%, the Dow Jones Industrial Average edged 0.31% lower, to finish the day at 16,279.89, and the S&P 500 closed at 1,938.76, down 0.20%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), DXCM: 86.71 (+1.03), GBSNU: 16.22 (-0.28), TMO: 124.49 (+2.39), A: 34.67 (+0.93), EXAS: 18.12 (-0.09)

Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma
PR Newswire - Tue Sep 22, 7:27AM CDT
ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28), GILD: 98.28 (+0.01), HZNP: 21.11 (+0.75), AEZS: 0.09 (unch), WGBS: 1.23 (-0.01)

Great Basin Announces Retention of Roth Capital Partners as Financial Advisor in Restructuring of the Company's Series C Warrants
Business Wire - Wed Sep 16, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it has retained Roth Capital Partners as financial advisor to assist in a restructuring of the Company's Series C Warrants. The Series C Warrants were issued as part of the Unit offering the Company completed on March 2, 2015. The Company is also preparing to file a proxy statement and hold a special shareholder meeting to seek approval to effect a reverse stock split and authorize additional common shares to meet its obligation to deliver common shares under the cashless exercise provision of the Series C Warrants.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Due Diligence Report: GBSN may be the Dark Horse to Win the Race - BrokerBank Securities
PR Newswire - Mon Sep 14, 7:35AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN) stock has received a strong recommendation of "buy" from two brokerage firm analysts and "hold" from another. Analysts agreed that the short term price target in GBSN is $8.25, but the stock price can fluctuate by $2.47 according to the standard deviation reading.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Scientific to Present at Three Investment Conferences in September
Business Wire - Fri Aug 28, 12:00PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that President and CEO Ryan Ashton and CFO Jeffrey Rona will speak at three upcoming investment conferences in New York City, including:
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Reports 2015 Second Quarter Results and Business Update
Business Wire - Wed Aug 12, 3:02PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN) (NASDAQ:GBSNU), a molecular diagnostic testing company, today reported earnings results for the quarter ended June 30, 2015 and provided a business update.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Announces Upcoming Separation of Publicly Traded Units
Business Wire - Thu Aug 06, 4:30PM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that its publicly traded units (the "Units" (symbol: GBSNU) will separate on August 25, 2015, as disclosed in the prospectus dated February 25, 2015, with each Unit separated into its component parts (eight Series C Warrants and one share of Series E Convertible Preferred Stock). In connection with the separation of the Units, the Units will be delisted from The Nasdaq Capital Market effective August 25, 2015.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Announces Business Update Call and Webcast
Business Wire - Wed Aug 05, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that it will report financial results for the second quarter ended June 30, 2015 after the market close on Wednesday, August 12, 2015. The Company also announced that it will host a business update call and webcast to discuss important operational progress and initiatives on the same day at 4:30 PM Eastern Time.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Technical Coverage on Medical Laboratories and Research Stocks -- Laboratory Corp. of America Holdings, DexCom, Bruker, WuXi PharmaTech, and Great Basin Scientific
PR Newswire - Tue Aug 04, 8:35AM CDT
Equity Research Institute has initiated coverage on the following equities: Laboratory Corporation of America Holdings (NYSE: LH), DexCom Inc. (NASDAQ: DXCM), Bruker Corporation (NASDAQ: BRKR), WuXi PharmaTech (NYSE: WX), and Great Basin Scientific Inc. (NASDAQ: GBSN). Free research report on Laboratory Corp. of America Holdings can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=LH On Monday, August 03, 2015, the NASDAQ Composite ended at 5,115.38, down 0.25%, the Dow Jones Industrial Average lost 0.52%, to finish the day at 17,598.20, and the S&P 500 closed at 2,098.04, down 0.28%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
GBSN: 0.09 (unch), DXCM: 86.71 (+1.03), BRKR: 16.84 (+0.53), LH: 112.29 (+2.11), WX: 43.57 (-0.04)

SeeThruEquity Initiates Coverage on Great Basin Scientific Inc. (NASDAQ: GBSN) with a Price Target of $9.38
ACCESSWIRE - Mon Jul 27, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / July 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Great Basin Scientific Inc. (NASDAQ: GBSN) with a 12 month price target of $9.38.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin elects Dr. Carlos B. Gonzalez as VP of Engineering
M2 - Thu Jul 16, 6:26AM CDT
Molecular diagnostics company Great Basin Scientific (Nasdaq:GBSN)(Nasdaq:GBSNU) reported on Wednesday the appointment of Dr. Carlos B. Gonzalez, Ph.D. as vice president of its Engineering.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Appoints Dr. Carlos B. Gonzalez as Vice President of Engineering
Business Wire - Wed Jul 15, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ:GBSN, GBSNU), a molecular diagnostics company, announced today that Carlos B. Gonzalez, Ph.D. has joined the Company's management team as Vice President of Engineering. Gonzalez brings more than 20 years of medical device engineering and research experience--including tenure at market leaders such as Abbott and Siemens--to the Utah-based company.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Announces Commercial Launch of Group B Strep Molecular Test
Business Wire - Wed Jul 08, 7:30AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, announced today its Group B Streptococcus (GBS) test--which received U.S. Food and Drug Administration (FDA) clearance in April--is now available to hospitals and laboratories in the U.S. Two laboratories have already converted their Group B Strep testing to Great Basin's molecular test, and as of July 7, more than 40 sites are in active evaluation or scheduled to evaluate the sample-to-result test for GBS. Further, the Company announced its customers evaluating the test are forecasting usage of the GBS test at volumes 50 percent greater than their usage of the Company's C. diff test.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Wins NIH Grant to Develop Direct from Whole Blood Test for Deadly CRE Superbug
Business Wire - Wed Jun 24, 7:30AM CDT
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), has awarded a research grant to Great Basin Scientific (NASDAQ:GBSN; GBSNU) and Brigham Young University (BYU), to develop a rapid molecular diagnostic test direct from whole blood for carbapenem-resistant Enterobacteriaceae (CRE). The NIH research grant (R01AI116989) will play a key role in meeting the goals of President Obama's recent National Action Plan for Combating Antibiotic-Resistant Bacteria.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin announces European patent protection for on-chip amplification technology
M2 - Wed Jun 17, 5:48AM CDT
Molecular diagnostics company Great Basin Scientific (NASDAQ:GBSN) revealed on Tuesday the receipt of the European Patent Office's notice to allow for patent application for its on-chip amplification technology that is currently patented in the US.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Great Basin Scientific awarded European patent; shares up 17%
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 9:07AM CDT

GBSN: 0.09 (unch)

Great Basin Scientific (GBSN) Stock Jumps After Receiving European Patent
at The Street - Tue Jun 16, 8:56AM CDT
Great Basin Scientific (GBSN) shares gain after the company announces the European Patent Office issued a notice to allow for application for its on-chip amplification technology.
GBSN: 0.09 (unch)

Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 8:24AM CDT

SYN: 2.46 (+0.29), GBSN: 0.09 (unch), COTY: 26.89 (-0.57), SUPN: 15.33 (+1.18), CAPL: 23.79 (+0.36), AERI: 19.35 (+0.88), AAVL: 8.49 (+0.46), NBG: 0.51 (+0.04), TAHO: 8.68 (+0.99), UCTT: 5.75 (+0.08)

Great Basin Granted European Patent Protection
Business Wire - Tue Jun 16, 7:30AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, announced today the European Patent Office has issued a notice to allow for application (#09711952.3) for the Company's on-chip amplification technology, currently patented in the U.S.
GBSN: 0.09 (unch), GBSNU: 16.22 (-0.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geothermal Energy Gets Boost with GRMS Adoption

Updated Category News Views 0

Geothermal's Big Leap with the GRMS The oil and gas sector didn't explode overnight—it leapt due to a consistent, standardized language that spoke to investors like a charm. Now, the geothermal industry is borrowing a page from this book of success with the Geothermal Resources Management System (GRMS). Finally, a framework not just built on hope and hot air, but...

Continue Reading
Hyliion Legal Woes Shake Investor Confidence

Updated Category News Views 0

Legal Storm Brews Over Hyliion Investments If you think riding the stock market is like sailing a calm sea, wake up. Hyliion Holdings Corp. (NYSE:HYLN) finds itself steaming headlong into rough waters. A securities class action lawsuit, Olmeta v. Hyliion Holdings Corp., accuses the company of embellishing its ambitions. The lawsuit cites potential wrongdoing in a...

Continue Reading
Mastering Power Efficiency with Phase Converters

Updated Category News Views 1

Powering Multiple Machines: A New Approach? You ever look at a workshop crammed with machines and wonder if it's all a waste of space, time, and money? Jay Yuergens from North America Phase Converter Co. gives us the lowdown on how one rotary or digital phase converter can handle the load. And let me tell you, it ain't as crazy as it sounds. It's all about finesse and...

Continue Reading
First Student Reduces Collisions by 63% with HALO Tech

Updated Category News Views 13

Making Every School Bus Ride Safer Here's some good news in the world of transportation, especially if you're keen on keeping kids safe on the daily school bus run. First Student's HALO™ Connected Transportation Platform claims it made a significant dent in reducing accidents—specifically, a 63% cut in forward collision risk. It's a big promise when you're talking...

Continue Reading
VIVIFY and ELISIUM Plan Hydrogen-Powered City

Updated Category News Views 1

Hydrogen Takes Center Stage in Urban Planning Well, I didn't see this one coming—a city that's planning the power before the buildings. We're talking about ELISIUM, the so-called cognitive city destined to rise in Hendry County, Florida. And leading the charge in all this energy planning? None other than VIVIFY Technology, set to bring in its hydrogen expertise right...

Continue Reading
New JPA Aims to Energize Inland Empire's Water Supply

Updated Category News Views 28

Fresh Steps in San Bernardino's Infrastructure Strategy Here's a twist for you: public agencies in San Bernardino County decided enough with the same old, same old and cooked up a new joint powers authority (JPA). They call it the San Bernardino Water and Power Authority, which sounds snappy enough for a meeting room nameplate, I reckon. Who's Steering the Ship? Leading...

Continue Reading
Plata Hits $1 Billion ARR in Record Digital Bank Growth

Updated Category News Views 14

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

Continue Reading
Honeywell Aerospace Faces Securities Fraud Lawsuit

Updated Category News Views 11

Turning Up the Heat on Honeywell Alright, strap in because things are getting tense over at Honeywell Aerospace (NASDAQ:HONA). Schall, Brown & Schwartz LLP (SBS) is stirring the pot with a class action lawsuit alleging some pretty deceptive business going-ons. From securities violations to misleading market statements, they aren’t holding back any punches. What’s This...

Continue Reading
Roof Inspections: Richmond's Key to Home Longevity

Updated Category News Views 17

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

Continue Reading
Ryan Stills: Vegan Powerlifter Defies Odds, Wins Sixth World Title

Updated Category News Views 12

Ryan Stills: A Comeback Story for the Ages Ryan Stills isn't just lifting weights; he's lifting the entire perception of what's possible after a heavy surgical setback. We're talking about a guy who stared down a hemi-shoulder replacement—a career ender for many—and came out the other side with a whole new set of gold medals. Two years ago, some might have written him...

Continue Reading

Top 5 Most Recently Viewed Articles

Children’s Place Sees Stock Surge Post Impressive Q2 Results

Updated Category News Views 56

Children’s Place Stock Rises After Strong Q2 Earnings Children’s Place, Inc. (NASDAQ: PLCE) has recently attracted a lot of attention as its stock prices soared following the release of its second-quarter earnings. The positive results came as a welcome surprise just before the market opened, leading to a notable increase in trading volumes. Strong Earnings Exceed...

Continue Reading
Yunji Inc. Confirms Compliance with Nasdaq Standards

Updated Category News Views 61

Yunji Inc. (NASDAQ: YJ) made headlines recently after confirming it had regained compliance with Nasdaq standards, signaling a significant recovery from non-compliance issues that had threatened its standing on the exchange. Compliance Rollercoaster: From Non-Compliance to Recovery Backtracking a bit, Yunji faced a stark reality when it was flagged by Nasdaq under Listing...

Continue Reading
Ladybug Nutratech Drives Revenue Growth with Strategic Plans

Updated Category News Views 43

Ladybug Nutratech Unleashes Revenue Growth Initiatives Ladybug Resource Group, Inc. (OTC PINK: LBRG), now known as Ladybug Nutratech, is swiftly positioning itself as a frontrunner in the health and wellness sector. The company has demonstrated an impressive revenue growth of $6.0 million, which reflects an extraordinary increase of 10,527% compared to the same timeline...

Continue Reading
New Findings Show Duvakitug's Efficacy for Inflammatory Bowel Disease

Updated Category News Views 87

Groundbreaking Results from the Duvakitug Study Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Sanofi SA (NASDAQ: SNY) have recently unveiled promising data from their RELIEVE UCCD Phase 2b study involving duvakitug, a new treatment for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), two prevalent types of inflammatory bowel disease (IBD)....

Continue Reading
Caliway's Innovative Weight Management Drug CBL-514 Advances Development

Updated Category News Views 126

Caliway's CBL-514 is Primed for Phase 2 Clinical Trial Caliway has recently completed its submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This submission is critical as it paves the way for a Phase 2 clinical study focusing on weight management using CBL-514, an innovative drug candidate designed to address...

Continue Reading